冠心通络胶囊结合双联抗血小板药物防治PCI术后支架内再狭窄的临床研究

Prevention and treatment of in-stent restenosis after PCI by Guanxintongluo capsule combined dual antiplatelet drugs

目的:研究冠心通络胶囊结合双联抗血小板药物防治经皮冠状动脉介入治疗(PCI)术后支架内再狭窄的临床疗效。方法:选择我院收治的82例行冠心病支架植入术患者,对所有患者进行数字编号,根据单双号法分为双联抗血小板药物组(40例)和联合治疗组(42例,在双联抗血小板组基础上联合冠心通络胶囊治疗),比较两组患者的疗效。结果:治疗后,与双联抗血小板组比较,联合治疗组支架再狭窄的总有效率(77.5%比95.2%)、心绞痛总有效率(80.0%比95.2%)、心电图总有效率(77.5%比92.9%)、中医症候总有效率(72.5%比90.5%)明显提高(P均<0.05)。两组患者治疗前后肝功能无明显差异(P>0.05)。结论:冠心通络胶囊结合双联抗血小板药物能显著降低经皮冠状动脉介入术后再狭窄的发生率,改善患者的中医症候、心电图变化,降低心绞痛疼痛程度,具有临床推广应用价值。

Objective： To study therapeutic effect of Guanxintongluo （GXTL） capsule combined dual antiplatelet drugs on prevention and treatment of in- stent restenosis after percutaneous coronary intervention （PCI）. Methods： A total of 82 patients with coronary heart disease undergoing stent implantation treated in our hospital were selected. All patients were numbered, and they were divided into dual antiplatelet group （n = 40） and combined treatment group （n = 42, received GXTL capsule based on dual antiplatelet group） according to odd and even number method. Therapeutic effect was compared between two groups. Results： Compared with dual antiplatelet group after treatment, there were significant rise in total effective rates of instent restenosis （77.5 % vs. 95.2 %）, angina pectoris （80.0% vs. 95.2%）, ECG （77. 5% vs. 92.9%） and syndrome of traditional Chinese medicine （72.5% vs. 90.5%） in combined treatment group, P〈 0.05 all. There were no significant difference in liver function between two groups before and after treatment, P〉0.05. Conclusion： Guanxintongluo capsule combined dual antiplatelet drugs can effectively reduce incidence rate of restenosis, improve syndrome of traditional Chinese medicine, ECG changes, reduce pain degree of angina pectoris in patients with coronary heart disease after PCI, which is worth extending.